Daewon Pharmaceutical Risk (Part 2): Ministry of Food and Drug Safety and National Tax Service ‘regulars’, ‘stigma’ of rebate companies… ‘disparaged’ for weak governance structure, backward family management, and low ESG ratings

2025.04.25 21:40:10
스팸방지
0 / 300